Literature DB >> 9148963

Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases.

C Zhang1, R A Baumgartner, K Yamada, M A Beaven.   

Abstract

Aggregation of the high affinity IgE receptor (FcepsilonRI) in a mast cell line resulted in activation of the p42 and the stress-activated p38 mitogen-activated protein (MAP) kinases. Selective inhibition of these respective kinases with PD 098059 and SB 203580 indicated that p42 MAP kinase, but not p38 MAP kinase, contributed to the production of the cytokine, tumor necrosis factor-alpha, and the release of arachidonic acid in these cells. Neither kinase, however, was essential for FcepsilonRI-mediated degranulation or constitutive production of tumor growth factor-beta. Studies with SB 203580 and the p38 MAP kinase activator anisomycin also revealed that p38 MAP kinase negatively regulated activation of p42 MAP kinase and the responses mediated by this kinase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148963     DOI: 10.1074/jbc.272.20.13397

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Regulation of mast cell survival and function by tuberous sclerosis complex 1.

Authors:  Jinwook Shin; Hongjie Pan; Xiao-Ping Zhong
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

2.  The effects of low-dose ionizing radiation in the activated rat basophilic leukemia (RBL-2H3) mast cells.

Authors:  Hae Mi Joo; Seon Young Nam; Kwang Hee Yang; Cha Soon Kim; Young Woo Jin; Ji Young Kim
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

3.  Differential pharmacological behaviour of p38 inhibitors in regulating the LPS-induced TNF-α production in human and rat whole blood in vitro.

Authors:  Mercè Pont-Giralt; Núria Godessart; Cristina Balagué
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

4.  Investigation into the involvement of phospholipases A(2) and MAP kinases in modulation of AA release and cell growth in A549 cells.

Authors:  Q G Choudhury; D T McKay; R J Flower; J D Croxtall
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis.

Authors:  T ten Hove; B van den Blink; I Pronk; P Drillenburg; M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

6.  Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice.

Authors:  H T Lu; D D Yang; M Wysk; E Gatti; I Mellman; R J Davis; R A Flavell
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

7.  Small molecules capable of activating DNA methylation-repressed genes targeted by the p38 mitogen-activated protein kinase pathway.

Authors:  Xiang Li; Erchang Shang; Qiang Dong; Yingfeng Li; Jing Zhang; Shaohua Xu; Zuodong Zhao; Wei Shao; Cong Lv; Yong Zheng; Hailin Wang; Xiaoguang Lei; Bing Zhu; Zhuqiang Zhang
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

8.  Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation.

Authors:  Luis Ulloa; Mahendar Ochani; Huan Yang; Mahira Tanovic; Daniel Halperin; Runkuan Yang; Christopher J Czura; Mitchell P Fink; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

9.  Negative control of mast cell degranulation and the anaphylactic response by the phosphatase lipin1.

Authors:  Jinwook Shin; Ping Zhang; Shang Wang; Jinhong Wu; Ziqiang Guan; Xiao-Ping Zhong
Journal:  Eur J Immunol       Date:  2012-11-26       Impact factor: 5.532

10.  Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580.

Authors:  R D Koranteng; E J Swindle; B J Davis; R J Dearman; I Kimber; B F Flanagan; J W Coleman
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.